SEC Filing Summary
Filing identity: The supplied filing is Gemphire Therapeutics Inc.’s Form 10-K, not Metavia Inc. Investors should verify the issuer before relying on this summary.
Business Context and Reporting Period
Annual report for the fiscal year ended December 31, 2016, filed March 20, 2017. Gemphire was a clinical-stage biopharmaceutical company developing gemcabene, a once-daily oral candidate for dyslipidemia and nonalcoholic steatohepatitis (NASH). The company had no approved products or commercial revenue.
Gemcabene was being evaluated for homozygous familial hypercholesterolemia, heterozygous familial hypercholesterolemia, atherosclerotic cardiovascular disease, severe hypertriglyceridemia and NASH. Three late-stage dyslipidemia trials were initiated in 2016.
Financial Performance and Position
| Metric | 2016 | 2015 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| General and administrative expense | $6.0 million | $3.2 million | +$2.8 million |
| Research and development expense | $8.7 million | $4.0 million | +$4.7 million |
| Total operating expenses | $14.7 million | $8.1 million | +$6.6 million |
| Net loss | $14.6 million | $9.0 million | +$5.6 million loss |
| Net loss attributable to common stockholders | $15.0 million | $13.0 million | +$1.9 million loss |
| Basic and diluted loss per share | $2.57 loss | $4.54 loss | Improved due primarily to higher share count and prior-period preferred-stock adjustments |
| Cash used in operating activities | $11.0 million | $5.4 million | +$5.6 million use |
| Cash and cash equivalents at year-end | $24.0 million | $3.6 million | +$20.4 million |
| Total liabilities | $4.1 million | $8.9 million | -$4.8 million |
There was no operating margin or gross margin because the company had no revenue. The company reported no debt at December 31, 2016; convertible notes had converted into common stock immediately before the IPO. Total stockholders’ equity was $20.6 million, compared with a $12.4 million deficit at year-end 2015.
Financing activities provided $31.5 million in 2016, including approximately $26.1 million of net IPO proceeds and $5.2 million of convertible-note proceeds. The company stated that year-end cash, together with a March 2017 private placement, was expected to fund operations through the dyslipidemia studies and the planned AZURE-1 NASH study, but additional capital would be required for further development and commercialization.
Material Changes Versus Prior Comparable Period
- Research and development expense increased 119%, primarily because of clinical-trial development, regulatory consulting, preclinical work and manufacturing activities.
- General and administrative expense increased 87%, reflecting increased staffing, professional services and public-company costs.
- Operating cash burn approximately doubled to $11.0 million.
- The company completed its initial public offering in August 2016, selling 3,027,755 shares in total and receiving approximately $26.1 million in net proceeds.
- Series A preferred stock and convertible notes converted into common stock before the IPO, eliminating the year-end preferred-stock and convertible-note balances.
- Share-based compensation increased to $1.7 million from $0.3 million.
- Fourth-quarter 2016 net loss was $7.2 million, including $4.8 million of research and development expense, versus a $2.6 million net loss in the fourth quarter of 2015.
Guidance, Outlook, Risks and Unusual Items
- Management expected top-line results from COBALT-1, ROYAL-1 and INDIGO-1 during 2017, initiation of the AZURE-1 NASH study in the second half of 2017, and AZURE-1 data in the second half of 2018.
- Management expected to seek End-of-Phase-2 meetings with the FDA and other regulators and anticipated Phase 3 registration trials no later than 2018, subject to trial results and regulatory agreement.
- Gemcabene remained subject to a partial clinical hold restricting trials longer than six months until two-year rat and mouse carcinogenicity studies were completed. Those studies were expected to finish by the end of 2017 and could affect longer-term trials, labeling or approval prospects.
- The company had not submitted an NDA and could not assure approval, successful commercialization or future profitability. It depended entirely on gemcabene, its only clinical product candidate.
- Management believed a cardiovascular outcomes trial would likely not be required before approval for its targeted dyslipidemia indications, but acknowledged that the FDA could require one. Such a trial would materially increase cost and delay.
- The Pfizer license required potential milestone payments of up to $37 million and tiered royalties ranging from the high single digits to low teens on future net sales. Pfizer could revoke the license if the company was unable to adequately commercialize gemcabene by April 2021.
- The company relied on contract research organizations and contract manufacturers, including one supplier for gemcabene drug substance, creating execution, quality and supply risks.
- On March 15, 2017, after year-end, the company raised approximately $12.5 million in a private placement of common-stock units with five-year warrants. The filing did not provide a clear post-financing cash balance.
Most Important Facts to Verify
- Confirm that the issuer is Gemphire Therapeutics Inc. rather than Metavia Inc.
- Verify the clinical results and statistical significance of COBALT-1, ROYAL-1 and INDIGO-1, as the 2016 filing primarily described planned or ongoing studies.
- Verify completion and regulatory impact of the required two-year carcinogenicity studies and the status of the partial clinical hold.
- Reconcile the company’s cash runway with actual 2017 spending, the March 2017 financing, warrant dilution and the additional capital needed for Phase 3 development.
- Review the Pfizer license for milestone triggers, royalty obligations, commercialization requirements and termination rights.
- Assess whether historical Phase 1 and Phase 2 efficacy and safety findings can be replicated in larger and longer clinical trials.
- Review patent and exclusivity durability, particularly the expected 2021 expiration of key licensed patents and the uncertainty around extensions and regulatory exclusivity.